Skip to content
Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Every year, the Clinical Trials on Alzheimer’s Disease conference (CTAD) brings together leaders in academia and industry to share and debate the latest in Alzheimer’s disease therapeutic trials. CTAD 2022 featured highly anticipated late-phase research news, as well as introductions to novel agents, ongoing studies, and cutting-edge clinical trial strategies.
Explore our coverage below!
FDA approves lecanemab for the treatment of Alzheimer’s disease
On January 6, 2023, the FDA approved lecanemab for the treatment of Alzheimer’s disease, making it the first ever treatment to clearly slow cognitive decline in a clinical trial…
Learn more
Mild Cognitive Impairment News
MCI, also known as prodromal Alzheimer’s disease, is becoming increasingly recognized as the key to early diagnosis and intervention in AD. Learn about the latest screening tools, biomarkers, and treatment strategies in MCI!
View more
Improving diagnosis & prognostication
View all